- AVIEW Enters Vietnam's Premium Screening Market, Securing a Bridgehead for Asian Expansion
- Gaining Competitiveness in the Hanoi Market Based on Experience and Technology from National Screening Programs
Coreline Soft announced on the 23rd that the 'GC&Phenikaa Healthcare Center' in Hanoi has adopted its AI-powered chest diagnosis platform, AVIEW LCS Plus.
The GC&Phenikaa Center was established based on a joint venture between Korea's GC Group and Vietnam's Phenikaa Group. It is drawing attention as a leading example aligning with the Vietnamese government's policies promoting smart hospitals and digital healthcare transformation. The center held its opening ceremony on the 5th of this month. Following deployments in premium centers in Gangnam and Gangbuk, Korea, this contract signifies an expansion into the Vietnamese premium screening market, demonstrating that the global healthcare visions of both companies have accelerated to the next level.
Vietnam is a rapidly growing market, driven by policies encouraging medical equipment imports and increasing demand for preventive and early screening. Premium screening centers, primarily located in Hanoi and Ho Chi Minh City, cater to high-income individuals, the middle class, and foreigners, and are actively adopting advanced imaging diagnostic technologies. GC I-MED recognized Vietnam's open medical environment as a new growth engine and decided on strategic investments to enter the local market. By collaborating with GC&Phenikaa Healthcare Center, a representative premium medical institution in Hanoi, they plan to present a new paradigm in Vietnam's AI screening market.
The newly adopted AVIEW LCS Plus is an integrated product capable of comprehensive analysis of lung nodules, emphysema, and coronary artery calcification (CAC) with a single low-dose chest CT scan. Its core technologies—automatic lesion detection and quantification, 3D visualization reports, and a user-friendly interface— enhance diagnostic accuracy and efficiency for medical staff. Simultaneously, the platform serves a communicative role, helping examinees intuitively understand complex medical information and actively participate in managing their health.
With the introduction of AVIEW LCS Plus, GC&Phenikaa Healthcare Center has established a next-generation screening environment capable of precise diagnosis of major chest diseases while minimizing radiation exposure.
"Through the opening of the Vietnam GC&Phenikaa Healthcare Center, we can now implement AI precision screening services in Vietnam at a level equivalent to those in Korea," said Yang Song-hyun, CEO of GC&Phenikaa Healthcare Center. "Using this successful first step in the Asian market as a springboard, we will set a new standard for global premium screening."
"GC&Phenikaa Healthcare Center is a representative premium center in Hanoi operating smart screening systems (including HIS, LIS, PACS, and RFID), making it an optimal partner to realize the clinical value of AVIEW LCS Plus," said Kim Jin-kook, CEO of Coreline Soft. "We will continue to spread the culture of AI early screening alongside our global partners, contributing to simultaneously improving medical access and quality."
Meanwhile, according to Grand View Research, the global AI healthcare market is projected to grow from $22.4493 billion in 2023 to $208.2259 billion by 2030, recording a CAGR of 37.5% during the 2024-2030 period. Diagnostic demand in the field of chest diseases, including lung cancer, is rapidly expanding due to aging populations, smoking rates, and environmental factors.
December 23, 2025
List